Taysha Gene Therapies, Inc.
TSHA
$3.00
$0.134.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.73% | 13.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.73% | 13.85% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -13.73% | 13.85% | |||
| SG&A Expenses | 5.39% | 102.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.14% | 8.06% | |||
| Operating Income | -24.89% | -7.47% | |||
| Income Before Tax | -24.86% | -14.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.86% | -14.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.86% | -14.61% | |||
| EBIT | -24.89% | -7.47% | |||
| EBITDA | -25.25% | -7.69% | |||
| EPS Basic | -12.89% | -14.14% | |||
| Normalized Basic EPS | -14.87% | -40.18% | |||
| EPS Diluted | -12.89% | -14.14% | |||
| Normalized Diluted EPS | -14.87% | -40.18% | |||
| Average Basic Shares Outstanding | 10.65% | 0.34% | |||
| Average Diluted Shares Outstanding | 10.65% | 0.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||